Alongside the data in PsA, UCB will present at EULAR new results demonstrating that Bimzelx delivered sustained clinical ...

Most people affected by psoriasis don’t pay much attention to the changes in their skin to begin with. But when the patches ...

"My intellectually disabled sister had frequent vomiting and fever, and her skin turned yellow. The ER doctor said it was a ...

Discover why nails separate from the nail bed, what causes onycholysis, and how to treat this common but concerning nail ...

The following is a summary of “Clinical and ultrasound features of a cohort of psoriasis patients without musculoskeletal ...

An analysis of key drug trials for psoriatic arthritis shows geographic disparities and racial gaps; most participants have ...

Enthesitis is a key, but often overlooked, feature of psoriatic arthritis. Learn how this inflammation at tendon and ligament attachment sites can affect diagnosis, symptoms, and treatment.

Late-breaking data reveal durable improvements in joint, skin, and quality of life outcomes with deucravacitinib.

Patients with uveitis had a higher risk for psoriatic arthritis and psoriasis, whereas those with psoriatic arthritis had a higher risk for uveitis.

Data from the Phase IIIb APEX study, presented at EULAR 2025, show that guselkumab (Tremfya) improved joint and skin symptoms and inhibited structural joint damage in patients with active psoriatic ...

Two studies suggest there is no significant benefit of early biologics over standard step-up care with methotrexate, but ...